Invention Grant
US08444978B2 Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
有权
抗CD160特异性化合物可从mAb CL1-R2获得的血管生成和免疫应用
- Patent Title: Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
- Patent Title (中): 抗CD160特异性化合物可从mAb CL1-R2获得的血管生成和免疫应用
-
Application No.: US13175221Application Date: 2011-07-01
-
Publication No.: US08444978B2Publication Date: 2013-05-21
- Inventor: Armand Bensussan , Laurence Boumsell , Phillipe Le Bouteiller
- Applicant: Armand Bensussan , Laurence Boumsell , Phillipe Le Bouteiller
- Applicant Address: FR Paris
- Assignee: INSERM (Institut National de la Santé et de la Recherche Médicale)
- Current Assignee: INSERM (Institut National de la Santé et de la Recherche Médicale)
- Current Assignee Address: FR Paris
- Agency: Marshall, Gerstein & Borun LLP
- Priority: EP04292015 20040809
- Main IPC: A61K39/00
- IPC: A61K39/00
Abstract:
The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production.
Public/Granted literature
- US20120003224A1 ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2 Public/Granted day:2012-01-05
Information query
